Disc Medicine Opco Inc, together with its subsidiaries, operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria. In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown, Massachusetts.